These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 32203863)

  • 21. Are the self-stigma and perceived stigma of patients treated with methadone or buprenorphine still a problem fifty years after the marketing authorization for opioid agonist treatment? The observational STIGMA study.
    Pinhal M; Schreck B; Leboucher J; ; Victorri-Vigneau C; Laforgue EJ; Grall-Bronnec M
    Addict Sci Clin Pract; 2024 Oct; 19(1):74. PubMed ID: 39415293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine.
    Sud A; Salamanca-Buentello F; Buchman DZ; Sabioni P; Majid U
    J Subst Abuse Treat; 2022 Apr; 135():108651. PubMed ID: 34728134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consumer attitudes about opioid addiction treatment: a focus group study in New York City.
    Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO
    J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 26. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding motivations and use typologies of gabapentin with opioid agonist medications.
    Ellis MS; Qureshi R; Buttram ME
    Drug Alcohol Depend; 2023 Jan; 242():109713. PubMed ID: 36462231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.
    Williams AR; Mauro CM; Feng T; Wilson A; Cruz A; Olfson M; Crystal S; Samples H; Chiodo L
    J Subst Abuse Treat; 2022 Aug; 139():108770. PubMed ID: 35337715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 30. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
    Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
    Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.
    Nayak SM; Huhn AS; Bergeria CL; Strain EC; Dunn KE
    Drug Alcohol Depend; 2021 Apr; 221():108649. PubMed ID: 33640679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants.
    Hall OT; Entrup P; Farabee K; Qin H; Rizvi H; Rausch J; Felkel WC; Teater J
    Subst Use Misuse; 2024; 59(2):312-315. PubMed ID: 37861246
    [No Abstract]   [Full Text] [Related]  

  • 33. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.
    Couch JV; Whitcomb M; Buchheit BM; Dorr DA; Malinoski DJ; Korthuis PT; Ono SS; Levander XA
    Harm Reduct J; 2024 Jun; 21(1):125. PubMed ID: 38937779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability in opioid use disorder clinical presentations and treatment in the emergency department: A mixed-methods study.
    Faude S; Delgado MK; Perrone J; McFadden R; Xiong RA; O'Donnell N; Wood C; Solomon G; Lowenstein M
    Am J Emerg Med; 2023 Apr; 66():53-60. PubMed ID: 36706482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals.
    Franz B; Dhanani LY; Hall OT; Brook DL; Fenstemaker C; Simon JE; Miller WC
    Addict Sci Clin Pract; 2024 Jan; 19(1):7. PubMed ID: 38243307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Pregnancy Recovery Center: A women-centered treatment program for pregnant and postpartum women with opioid use disorder.
    Krans EE; Bobby S; England M; Gedekoh RH; Chang JC; Maguire B; Genday P; English DH
    Addict Behav; 2018 Nov; 86():124-129. PubMed ID: 29884421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.